Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week randomized, blinded, placebo-controlled study of inhaled CSJ117 in adults with COPD
2021-000692-36Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2021
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ecleralimab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in E-RS score. Started Aug 2021; status: completed.
02
Drugs
ecleralimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2021-000692-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000692-36.